CNX Therapeutics appoints Ben Moore as Vice President, Corporate Development
CNX Therapeutics is proud to announce that Ben Moore has joined CNX Therapeutics as our Vice President, Corporate Development. Ben will be leading CNX’s acquisition and strategic growth activities, as we look to build on our existing European platform by providing a broader portfolio of high-quality CNS and specialist-initiated medicines to improve patient lives.
Ben has worked in the pharmaceutical industry for over 15 years and joins from Mundipharma International where he was Senior Director, Corporate and Business Development. Ben has also previously held international roles at Zentiva, MSD and GSK with broad experience across innovative medicines, established and OTC products.
Ben says “CNX Therapeutics aspires to be a European leader in bringing speciality hospital and CNS products to patients. I’m very inspired by this vision and look forward to the opportunity to help drive the company’s growth ambitions and to establish us as a major player within the speciality pharma sector. With a strong team in place and the passion and enthusiasm to make a difference, I’m confident in the future for CNX.”